Brief: Merck Presents One-Year Results From The Pivotal Phase 2B/3 Brunello Study Evaluating Remigromig
10/10/2026 23:11
BRIEF-Merck Presents One-Year Results From The Pivotal Phase 2B/3 Brunello Study Evaluating Remigromig Oct 10 (Reuters) - Merck & Co Inc MRK.N:
MERCK PRESENTS ONE-YEAR RESULTS FROM THE PIVOTAL PHASE 2B/3 BRUNELLO STUDY EVALUATING REMIGROMIG, A TRI-SPECIFIC AGONIST OF THE WINGLESS-RELATED INTEGRATION SITE (WNT) PATHWAY, IN ADULTS WITH DIABETIC MACULAR EDEMA AT AAO 2026
MERCK & CO - REMIGROMIG DEMONSTRATES NON-INFERIOR VISUAL ACUITY VERSUS RANIBIZUMAB AT ONE YEAR IN DME
Source text: ID:nBw6VpKjBa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines